{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Parigger L"],"funding":["Österreichische Forschungsförderungsgesellschaft"],"pagination":["1061142"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9794616"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9"],"pubmed_abstract":["<h4>Introduction</h4>The current coronavirus pandemic is being combated worldwide by nontherapeutic measures and massive vaccination programs. Nevertheless, therapeutic options such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main-protease (M<sup>pro</sup>) inhibitors are essential due to the ongoing evolution toward escape from natural or induced immunity. While antiviral strategies are vulnerable to the effects of viral mutation, the relatively conserved M<sup>pro</sup> makes an attractive drug target: Nirmatrelvir, an antiviral targeting its active site, has been authorized for conditional or emergency use in several countries since December 2021, and a number of other inhibitors are under clinical evaluation. We analyzed recent SARS-CoV-2 genomic data, since early d"],"journal":["Frontiers in medicine"],"pubmed_title":["Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs."],"pmcid":["PMC9794616"],"funding_grant_id":["41404876"],"pubmed_authors":["Parigger L","Gruber CC","Krassnigg A","Schopper T","Gruber K","Tappler K","Singh A","Hetmann M","Steinkellner G","Kochl K"],"additional_accession":[]},"is_claimable":false,"name":"Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs.","description":"<h4>Introduction</h4>The current coronavirus pandemic is being combated worldwide by nontherapeutic measures and massive vaccination programs. Nevertheless, therapeutic options such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main-protease (M<sup>pro</sup>) inhibitors are essential due to the ongoing evolution toward escape from natural or induced immunity. While antiviral strategies are vulnerable to the effects of viral mutation, the relatively conserved M<sup>pro</sup> makes an attractive drug target: Nirmatrelvir, an antiviral targeting its active site, has been authorized for conditional or emergency use in several countries since December 2021, and a number of other inhibitors are under clinical evaluation. We analyzed recent SARS-CoV-2 genomic data, since early d","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-31T23:12:59.608Z","creation":"2024-11-12T07:22:12.129Z"},"accession":"S-EPMC9794616","cross_references":{"pubmed":["36590977"],"doi":["10.3389/fmed.2022.1061142"]}}